Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.41 |
| ▸ | TSHR | P16473 | 8/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14631792 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CYP3A4TSHRPIK3CAMAPK1 | |
| SCHEMBL16982944 | 0.79 | ALDH1A1 (0.39) | ALDH1A1HPGD | |
| SCHEMBL3971917 | 0.77 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TSHRPIK3CAMAPK1 | |
| SCHEMBL17649942 | 0.77 | TSHR (0.40) | ALDH1A1CYP3A4TSHRMAPK1TP53 | |
| SCHEMBL159338 | 0.75 | TSHR (0.39) | ALDH1A1CYP3A4TSHRMAPK1TP53 | |
| SCHEMBL2906897 | 0.75 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRPIK3CAMAPK1 | |
| SCHEMBL8249512 | 0.75 | HTR2A (0.41) | ALDH1A1CYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL13755137 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2361143 | 0.75 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRPIK3CAMAPK1 | |
| SCHEMBL6399331 | 0.75 | CYP3A4 (0.39) | ALDH1A1CYP3A4TSHRPIK3CAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| EP-4493182-A1 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | Huyabio International, LLC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20140275534-A1 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY) PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO., LTD. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140058129-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8586782-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-11-19 | — | — | US | disclosed |
| US-8362294-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | MONOVICH LAUREN G (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2046723-B1 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| CN-101479231-A | Phenylacetic acid derivatives as COX-2 inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| EP-2046723-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008002853-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058129-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | ALDH1A1 37/4885CYP3A4 86/4885TSHR 2476/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885CYP3A4 684/4885TSHR 1114/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885CYP3A4 684/4885TSHR 1114/4885 |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | ALDH1A1 37/4885CYP3A4 86/4885TSHR 2476/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | ALDH1A1 1370/4885CYP3A4 715/4885TSHR 1131/4885 |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, PTGER2 | ALDH1A1 36/4885CYP3A4 82/4885TSHR 2586/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885CYP3A4 684/4885TSHR 1114/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | ALDH1A1 4276/4885CYP3A4 4304/4885TSHR 2333/4885 |
| US-20140275534-A1 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY) PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | EGFR, ERBB2, ERBB3 | ALDH1A1 445/4885CYP3A4 1913/4885TSHR 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.